Pluristem gets clearance for Indian studies for placenta-based cell therapy
This article was originally published in Scrip
Executive Summary
Pluristem Therapeutics of Israel has received approval from India’s health ministry for a phase II trial with its PLX (placental expanded) cells for the treatment of thromboangiitis obliterans (Buerger's disease).